Could OKYO Pharma’s urcosimod finally crack a painful eye disease with no approved therapy?
OKYO Pharma’s urcosimod moves toward Phase 3 as the biotech targets neuropathic corneal pain, a severe ocular condition without approved therapy.
Pharma & Biotech